The adenosine receptor antagonist caffeine, which acts through A1 and A2A, has been shown to improve cognitive function in AD sufferers and reduce Aβ load and tau burden while improving cognition in transgenic animal models [86]. The gene discussed is MAPT; the disease is Alzheimer disease.